Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous immunoglobulin plus prednisone vs prednisone in newly diagnosed idiopathic inflammatory myopathy
2024-516057-42-00Phase 2Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Autoimmune Myopathies, dermatomyositis (DM), antisynthetase syndrome (ASSD) and 4 more comparing IVIG + prednisone with Prednisone + placebo (2 arms). Primary endpoint: Total improvement score at 12 weeks. Started Oct 2024; status: completed.
02
Drugs
immune globulin
03
Conditions
Autoimmune Myopathiesdermatomyositis (DM)antisynthetase syndrome (ASSD)immune-mediated necrotizing myopathy (IMNM)Overlap Myositis (OM)
Beyond the preview
Go deeper on 2024-516057-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516057-42-00.